CADL...$12.33...🥳...Another Runner on the Cup N Handle Breakout...
georgie18
Member Level Re: georgie18 post# 178
Wednesday, February 19, 2025 11:56:55 AM
Post# 179 of 179 CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...
georgie18
Member Level Re: georgie18 post# 30792
Tuesday, February 18, 2025 9:52:58 AM
Post# 32134 of 32233 CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...
georgie18
Member Level Re: georgie18 post# 160
Wednesday, January 22, 2025 10:41:18 AM
Post# 165 of 177 CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025 Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026 The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025 The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027 NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
Market Data 
Markets 
AI
